Navigation Links
Mouse study offers new clues to cognitive decline
Date:5/8/2014

New research suggests that certain types of brain cells may be "picky eaters," seeming to prefer one specific energy source over others. The finding has implications for understanding the cognitive decline seen in aging and degenerative diseases such as Alzheimer's and multiple sclerosis.

Studying mice, investigators from Washington University School of Medicine in St. Louis showed that a specific energy source called NAD is important in cells responsible for maintaining the overall structure of the brain and for performing complex cognitive functions. NAD (nicotinamide adenine dinucleotide) is a molecule that harvests energy from nutrients in food and converts it into a form cells can use.

The work appears in two journal articles in the May 8 issue of The EMBO Journal, a publication of the European Molecular Biology Organization, and in a recent issue of The Journal of Neuroscience.

"We are interested in understanding how cells make NAD and what implications that has for cellular function, especially in the context of aging and longevity," said Shin-ichiro Imai, MD, PhD, professor of developmental biology and of medicine and senior author of both papers. "We know, for example, NAD levels decrease with age in tissues such as muscle and fat. We wanted to find out if the same is true in the brain."

The investigators looked at two types of brain cells: adult neural stem cells, responsible for maintaining supplies of neurons and their supporting cells, and forebrain neurons, vital for performing complex cognitive tasks.

In The EMBO Journal, they reported that NAD levels decreased with age in the mouse hippocampus, a vital region of the brain for cognition. The researchers then used genetic techniques to find out what would happen when NAD manufacturing is turned off in the adult neural stem cells of the mouse brain.

"Neural stem cells are very metabolically expensive, so you might expect them to be particularly vulnerable to loss of an energy source," said first author Liana Roberts Stein, PhD, postdoctoral researcher in Imai's lab. "There are other energy sources for brain cells, such as glucose, but no one had ever looked at where NAD is coming from in these cells."

According to the researchers, there are four pathways of NAD synthesis, and the scientists focused on just one. They wanted to find out whether this particular pathway a longtime focus of Imai's lab is important for these cells or if the other routes could compensate.

The pathway begins with the B vitamin nicotinamide. Cells take dietary nicotinamide and, with a helper protein called Nampt, manufacture a molecule called NMN, which then is processed further to make NAD. When Stein eliminated Nampt from neural stem cells, several significant changes took place.

Levels of NAD dropped, and the neural stem cells stopped dividing; they stopped renewing themselves; and they stopped being able to create important cells that insulate axons, the "wires" that carry electrical signals throughout the brain. With less insulation, these signals slow down, impairing brain function.

Imai and Stein pointed out possible therapeutic implications of this finding, especially in light of what is known about cognitive decline in aging and certain diseases.

"Scientists have shown that with age there actually isn't a large decrease in the total neuron population," Stein said. "But there is quite a substantial decrease in white matter, which is primarily composed of cells that function in axon insulation. This pathway also could be relevant in conditions involving loss of cells that make this insulation, like multiple sclerosis."

Imai and Stein also found they could prevent the loss of the neural stem cells missing Nampt by giving the mice NMN, the next molecule in the chain of events leading to NAD.

"We gave the mice NMN in their drinking water for 12 months," Stein said. "And at the higher dose, we saw a rescue of the neural stem cell pool in aged mice."

Imai called this finding exciting because it supports the possibility of a future NMN supplement.

"We think that NMN could convey a similar effect in people," Imai said. "A future clinical trial for NMN will tell us if it has any efficacy in humans."

In addition to maintaining stem cell populations and keeping the brain supplied with all its cell types, the investigators showed that NAD also is vital for the process of cognition itself.

Reporting in The Journal of Neuroscience, they showed that neurons of the mouse forebrain depend heavily on NAD in normal cognitive function. Instead of deleting Nampt in stem cells, this time Stein deleted it only in neurons of the forebrain. All other cells were normal, including those that make axon insulation.

Without Nampt and its eventual product, NAD, in forebrain neurons, the behavior of the mice changed dramatically, according to the investigators.

"The mice were really hyperactive, with a twofold increase in activity levels," Stein said. "They also showed a loss of anxiety-like behaviors. These mice didn't seem to sense or fear potentially threatening situations and showed fairly drastic memory defects."

Stein pointed out that these neurons are in a region of the brain known to be particularly vulnerable to neurodegenerative conditions from Alzheimer's disease to stroke.

"It's possible that these neurons' dependence on Nampt is responsible for their extreme susceptibility to these conditions," she said. "It would be interesting to model some of these diseases in mice and see if supplementing NMN provides any benefit to their behavior or memory."

"We haven't done that study yet," Imai added. "But this is the direction the entire field is going."


'/>"/>

Contact: Julia Evangelou Strait
straitj@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert  

Related medicine news :

1. A novel transgenic mouse model of Chinese Charcot-Marie-Tooth disease type 2L
2. A versatile mouse that can teach us about many diseases and drugs
3. Building a better mouse model to understand pancreatic cancer
4. Researchers identify fundamental differences between human cancers and genetically engineered mouse models of cancer
5. Heated Mouse: Introducing ValueRays® Executive Series Heated Computer Mice
6. Knockout mouse grows larger, but weaker, muscles
7. UCLA and Chinese scientists analyze genetic makeup of human and mouse embryos in amazing detail
8. New mouse model reveals a mystery of Duchenne muscular dystrophy, Stanford scientists say
9. Got an Itch? Mouse Study May Help Explain Why
10. New mouse model confirms how type 2 diabetes develops
11. Transparent Mouse Brain Could Shed Light on Human Brain Health
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Mouse study offers new clues to cognitive decline
(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: